NeuroSearch Says Huntexil Results Support Conclusions of Individual Trials

NeuroSearch A/S said the results of a meta-analysis with its Huntexil treatment for Huntington’s disease support the conclusions drawn from each individual trial, with better precision due to the larger number of observations.

NeuroSearch now plans to present and discuss the Huntexil data with regulators during the first half of 2011.

To contact the editor responsible for this story: Christian Wienberg at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.